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137Cs source, respectively. The spatial resolution of this 
detector so far has been determined to be about 5 mm, using 
the k-nearest-neighbour algorithm (k-NN) [1]. 
Moreover, the Compton camera has been commissioned at 
different particle beam facilities. The time-of-flight (TOF) 
capability of the system was evaluated at the Garching 
Tandem accelerator, using a 20 MeV pulsed (400 ns) deuteron 
beam hitting a water phantom, showing prompt γ rays well 
separated from the slower neutrons. The camera was further 
tested with different clinical proton beams from the research 
area of the University Proton Therapy Dresden (100, 160 and 
225 MeV) stopping in either a water or a PMMA phantom, as 
indicated in Fig.1. For all three proton beam energies, the 
analysis of the prompt γ energy versus the TOF showed no 
significant neutron background. The Compton electron 
energy loss was extracted from each DSSSD layer, showing a 
gradual sequential increase of the energy loss from the first 
to the last layer.  
 
 
Figure 1: The Compton camera, enclosed in a Faraday light 
tight cage, is placed under 90o relative to the proton beam 
that hits a water phantom (here at the OncoRay facility, 
Universitäts Protonen Therapie Dresden). 
 
Conclusion: A Compton camera is under development in 
Garching, designed for online ion beam range verification via 
prompt γ detection. The monolithic LaBr3 detector was 
characterized in the laboratory exhibiting excellent energy 
and time resolution as well as a sufficient position resolution. 
The Compton camera was commissioned with a low-energy 
pulsed deuteron beam at the Garching Tandem accelerator 
and with high-energy clinical proton beams at the OncoRay 
facility, Dresden.  
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Purpose: Particle therapy provide a more favorable dose 
distribution compared to x-rays, but limited focus has been 
on the actual biological responses. Effects of carbon ion 
radiation in experimental tumor models has been 
investigated in a limited number of studies, the majority of 
these with tumor growth delay as biological endpoint. To 
elucidate the biological variation in radiation response in 
particle therapy, more in vivo studies are needed. The aim of 
the present study was to compare the biological 
effectiveness of carbon ions relative to x-rays between the 
clinical relevant endpoint tumor control and normal tissue 
damage, both acute and late effects. 
Materials and Methods: CDF1 mice with C3H mouse mammary 
carcinoma placed subcutaneously on the foot of the right 
hind limb were irradiated with single fractions of either 
photons or 12C ions, using a 30-mm spread-out Bragg peak. 
Endpoint of the study was local control (no tumor recurrence 
within 90 days). For the acute skin reaction, non-tumor 
bearing CDF1 mice were irradiated with a comparable 
radiation scheme, and monitored for acute skin damage. Late 
radiation induced fibrosis was measured up to 322 days 
following treatment.  
Results: The TCD50 (dose producing tumor control in 50% of 
mice) values with 95% confidence interval were 29.7 (25.37- 
34.78) Gy for C ions and 43.94 (39.24- 49.2) Gy for photons. 
The corresponding RBE values were 1.48 (1.28-1.72). For 
acute skin damage the MDD50 (dose to produce moist 
desquamation in 50% of mice) values with 95% confidence 
interval were 26.34 (22.99-30.19) Gy for C ions and 35.84 
(32.94-38.98) Gy for photons, resulting in a RBE of 1.36 
(1.20-1.45). For late radiation-induced fibrosis the FD50 (dose 
to produce severe fibrosis in 50% of the mice) with 95% 
confidence interval were 26.5 (23.1 – 30.3) Gy for carbon ions 
and 39.8 (37.8 – 41.8) Gy for photons, with a RBE of 1.50 
(1.33 – 1.69).  
Conclusions: We have established TCD50, MDD50 and FD50 
values for local tumor control and normal tissue damage and 
the corresponding RBE values for carbon ions in a mouse 
model. The observed RBE values were very similar for tumor 
response, acute skin damage and late RIF when irradiated 
with large doses of high- linear energy transfer (LET) carbon 
ions. This study add information to the variation in biological 
effectiveness in different tumor and normal tissue models. 
(Acta Oncologica, In Press) 
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The Proton Therapy Facility at TRIUMF is now in routine 
operation treating ocular tumours using 74 MeV protons 
extracted from the 500 MeV H- cyclotron. In this work, the 
feasibility of using PET scanning for proton dose monitoring is 
investigated. Different lucite phantoms have been irradiated 
with a raw Bragg peak and a spread out Bragg peak of 74 MeV 
and scanned using two PET scanners at UBC hospital. 
Simulation programs GEANT4 and FLUKA are being used to 
validate against experimental measurements. GEANT4 has 
been coupled with EXFOR cross section data of proton 
induced reactions to calculate the axial activity of the 
phantoms. Despite the very simple setup, significant 
discrepancies between the codes have been observed for the 
activity profiles of 11C and 15O and 13N, whereas the beam 
range in lucite has been found to have good agreement.  
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Functional multimodal imaging was used to assess early 
response to radiation treatment in the murine prostate 
tumour model CWR22.  
Positron Emission Tomography (PET)/Computer Tomography 
(CT) and Dynamic Contrast-Enhanced Ultrasonography (DCE-
US) were employed to determine the relationship between 
metabolic and microvascular parameters that reflect the 
tumour microenvironment, followed by immunohistochemical 
validation of microvessel density (MVD) and necrosis. Two 
experimental groups were tested according to the tracers 
used in PET/CT: 18Fluorine-Fluoromisonidazole (18F-FMISO) 
and 18F-Fluorocholine (18F-FCH) which are associated with 
hypoxia and choline metabolism, respectively [1,2]. PET/CT 
and DCE-US were acquired at day 0 and day 3. At day 1, 
radiation treatment was delivered as a single fraction of 10 
Gy. PET/CT and DCE-US acquisition and quantification were 
performed as previously described [3,4]. Wilcoxon’s 
matched-pairs test was used to determine intergroup 
differences at day 0 and day 3, and to assess intragroup 
differences from day 0 to day 3. Kendall’s Tau-b test was 
employed to assess correlation between functional 
parameters derived from PET/CT and DCE-US. In addition, 
the relationship between functional and histological 
parameters was also tested. Bonferroni correction for 
multiple testing was employed and a significance level of 5% 
was considered in all tests. 
In the 18F-FMISO group, the maximum Standardized Uptake 
Values (SUVmax) and the mean SUV (SUVmean) were 
decreased for the treated mice, suggesting a decrease in 
hypoxia. Furthermore, the SUVmean of the tumour-to-muscle 
ratio was correlated to MVD at day 3. In addition, the 
eliminating rate constant of the contrast agent from the 
plasma kel derived from DCE-US was correlated to the 
SUVmean of tumour-to-muscle ratio, necrosis, and MVD. In 
the 18F-FCH group; heterogeneous and reduced tracer uptake 
was detected. The kurtosis of the amplitude of the contrast 
uptake A linked to DCE-US was significantly decreased for the 
control mice.  
Our results demonstrated that the multimodal approach using 
18F-FMISO PET/CT and DCE-US has valuable diagnostic and 
prognostic potential for early non-invasive evaluation of 
radiotherapy. 
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The aim of this work is to study the effects of gold 
nanoparticles (GNPs) on cell viability in choroidal melanoma 
which is irradiated with cobalt source with Monte Carlo and 
In Vitro studies.  
In the Monte Carlo phase of this study a cylinder with the 
radius of 1.7 cm and the length of 2.1 cm was simulated as 
tumor phantom through with MCNP5 code and was filled with 
the tumor composition which obtained from previous work. In 
a discrete simulation such a phantom was divided into three 
parts and the middle region was latticed and filled with 
different concentrations of 50, 100, 200, 400 and 600 μg 
GNPs with 50nm in diameter. In both simulations the array of 
0.5*0.5*0.5 mm^3 voxels were utilized for scoring the 
average energy deposition to calculate the depth dose. The 
AECL Thetaron 60Co external radiation therapy device with 
the distance of 80 cm from the center of the Phantom has 
been considered as radiation source. The dose value to these 
voxels was calculated utilizing F6 tally. The dose 
enhancement factor (DEF) which is defined as the ratio of the 
dose in a particular region of a tissue when GNPs are present 
to the same factor in the absence of such substances were 
calculated and compared for different concentrations. In the 
in-vitro study, GNPs were synthesized following the FERN 
method, by employing HAuCl4 gold halides that were then 
reduced by sodium citrate. Cancerous melanoma cells were 
extracted from a middle-aged human female and digested by 
the use of the Tripezyn enzyme. The noted cells were 
cultured under a DMEM environment within a T75 flask with 
an FBS of 20%, and were incubated in an atmosphere 
consisting of 5% CO2, under a steady temperature of 37 C. 
Melanoma cells were cultured in a 96-well plate, and 
received the required GNPs with specific concentrations of 
600, 400, 200, 100 and 50μg through injection. The toxicity 
of the mentioned particles on the cells was then evaluated 
using a MTT Assay. The plate were then irradiated by the 
cobalt source in the presence and absence of GNPs. 48 hours 
and a week after irradiation, viability of the cells were 
assayed with MTT test again.  
In both Monte-Carlo and in-vitro studies it was observed that 
the presence of GNPs could play an important role in dose 
enhancement and decrease the viability of cancerous cells. 
When the concentration of nanoparticles increases in the 
area of the tumor, a higher amount of radiation energy will 
be absorbed in the tumor area. As a result, the amount of 
the dose absorbed by the normal tissue will be decreased.  
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Purpose: The effects of gold nanoparticles (GNPs) on human 
choroidal melanoma which are irradiated with a diode laser 
beam of 810nm wavelength has been examined with both 
Monte Carlo and In Vitro studies.  
Material and Method: In the Monte Carlo phase of this work, a 
human eye phantom has been simulated through with Geant4 
code and a tumor with the apical height of 0.5mm was 
defined on the equator temporal to the eyeball. The tumor 
was latticed by identical cubes each with a volume of 0.1cm3 
and different concentrations of gold nanoparticles were 
